Desensitization of β2‐adrenoceptor‐mediated responses by short‐acting β2‐adrenoceptor agonists in human lung mast cells
Open Access
- 1 February 2003
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 138 (3) , 512-520
Abstract
The principal aim of the present study was to determine whether long‐term treatment of human lung mast cells (HLMC) with the clinically‐relevant β2‐adrenoceptor agonists, salbutamol and terbutaline, leads to desensitization of β2‐adrenoceptor‐mediated responses in these cells. The non‐selective β‐adrenoceptor agonist, isoprenaline, and the selective β2‐adrenoceptor agonists, salbutamol and terbutaline, inhibited the IgE‐mediated release of histamine from HLMC. Salbutamol (pD2; 7.7±0.3) and terbutaline (pD2; 7.3±0.2) were roughly equipotent as inhibitors of histamine release although both agonists were less potent than isoprenaline (pD2; 8.6±0.2). Isoprenaline (10−5 M), salbutamol (10−5 M) and terbutaline (10−5 M) enhanced total cell cAMP levels in HLMC over basal by 361±90, 150±38 and 165±35%, respectively. Long‐term exposure (24 h) of HLMC to either salbutamol (10−7 M) or terbutaline (10−7 M) led to a subsequent reduction in the effectiveness of salbutamol and terbutaline (both 10−9–10−4 M) to inhibit histamine release. However, salbutamol was significantly (P2‐adrenoceptor density in cell membranes after pretreatment (24 h) of cells with either salbutamol (10−6 M) or terbutaline (10−6 M). Both agonists reduced β2‐adrenoceptor density in membranes to about the same extent (∼25% reduction) but these changes in receptor density were not statistically significant (P>0.05). These data indicate that long‐term exposure of mast cells to salbutamol causes greater levels of desensitization to β2‐adrenoceptor‐mediated responses in HLMC than terbutaline. These findings may have wider clinical significance in the context of asthma treatment as compromised mast cell inhibition could result following long‐term exposure of mast cells to short‐acting bronchodilators. British Journal of Pharmacology (2003) 138, 512–520. doi:10.1038/sj.bjp.0705050Keywords
This publication has 36 references indexed in Scilit:
- Chronic systemic administration of salmeterol to rats promotes pulmonary β2‐adrenoceptor desensitization and down‐regulation of GsαBritish Journal of Pharmacology, 2001
- Albuterol-induced downregulation of Gsα accounts for pulmonary β2-adrenoceptor desensitization in vivoJournal of Clinical Investigation, 2000
- Effect of β agonists on inflammatory cellsJournal of Allergy and Clinical Immunology, 1999
- Influence of receptor reserve on β‐adrenoceptor‐mediated responses in human lung mast cellsBritish Journal of Pharmacology, 1998
- Salmeterol inhibition of mediator release from human lung mast cells by β‐adrenoceptor‐dependent and independent mechanismsBritish Journal of Pharmacology, 1998
- β2-Adrenergic Receptor Desensitization, Internalization, and Phosphorylation in Response to Full and Partial AgonistsJournal of Biological Chemistry, 1997
- Protection by dexamethasone of the functional desensitization to β2‐adrenoceptor‐mediated responses in human lung mast cellsBritish Journal of Pharmacology, 1997
- Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthmaTrends in Pharmacological Sciences, 1996
- Isolation and properties of cardiac and other mast cells from the rat and guinea-pigInflammation Research, 1985
- β-Adrenergic Receptors Concerned with the Anaphylactic MechanismInternational Archives of Allergy and Immunology, 1973